In gliomas, p53 wild-type cells are more sensitive to TMZ, but more resistant to ACNU than p53 mutant cells, which was explained by up-regulation of CD95 death receptor or DNA repair (Batista et al, 2007; Roos et al, 2007a). The gene discussed is TP53; the disease is central nervous system cancer.